RE:RE:RE:ONCY pelareorep + CAR-T therapy as explained by Mayo ClinicDespite opening additional centers, CAR-T manufacturers can’t guarantee enough supply for all treatment centers and patients. But production capacity isn’t the only manufacturing problem for a currently marketed CAR-T product like Carvykti. Elizabeth Budde, M.D., Ph.D., who chairs City of Hope’s clinical cellular immunotherapy committee noted that her team has had more discussions with J&J than with BMS about "out-of-specification" orders, or those that don't meet strict manufacturing requirements.
“One of the main reasons is, again, you make a patient wait so long to get the product, and then they notify you the product is out-of-spec. That’s very disappointing and disheartening,” Budde said.
An out-of-spec CAR-T is no longer considered a commercial product and can only be given to a patient under special protocols without payer coverage.
Despite the problems, BCMA CAR-T remains a seller’s market where doctors don’t have a choice but to use all available supplies.
This restricted environment for CAR-T therapy opens the door for the use of pelareorep in combination of CAR-T therapy for an effective combination therapy treatment option.
https://www.fiercepharma.com/pharma/johnson-johnson-bristol-myers-kite-pharma-car-t-cell-therapy-struggle-sloan-kettering